Cancer stem cells have implications in clinical settings. Only a small portion (<1%) of tumor cells can form new tumors, known as tumor initiating cells or cancer stem cells. These cells express specific cell surface markers that can be identified using flow cytometry and fluorescence-activated cell sorting. Targeting cancer stem cells is important for therapy because they are resistant to chemotherapy and radiation. Combination therapies that target cancer stem cell pathways such as Hedgehog and Wnt signaling or aldehyde dehydrogenase activity may be more effective treatments.